A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Status:
Completed
Trial end date:
2017-09-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether it is better to receive a new drug, BBI608,
in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as
second line treatment for gastric and gastroesophageal junction cancer after prior first line
platinum and fluoropyrimidine based chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc